Evolocumab for coronary artery disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 27 Jun 2018: Trial registered, NCT03570697
  2. 19 Nov 2018: Trial started, NCT03570697

The trials

NCT03570697: Imaging of Coronary Plaques in Participants Treated With Evolocumab

State
Completed
Phase
Phase 3
People
164 taking part
Started
19 Nov 2018
Primary completion
18 Dec 2020
Arms
Evolocumab
Results
Posted on the registry
  1. 27 Jun 2018: Trial registered
  2. 19 Nov 2018: Trial started
  3. 21 Jan 2021: Trial completed
  4. 24 Nov 2021: Trial results posted

NCT04141579: Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction With a PCSK9 Antibody

State
Completed
Phase
No phase
People
150 taking part
Started
10 Nov 2020
Primary completion
9 Nov 2023
Arms
Treatment arm
Results
None posted
  1. 28 Oct 2019: Trial registered
  2. 10 Nov 2020: Trial started
  3. 9 Nov 2023: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as Evolocumab 140 MG/ML [Repatha], Repatha.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.